Back to today’s briefing

Story perspectives

Eli Lilly sues six firms, customs seize over 2,000 shipments

8/12/2026

31 4 Full Breakdown

Summary

Story summary

Eli Lilly filed six lawsuits in California and Texas against U.S. sellers of black-market retatrutide.
The suits target six entities, including Aesthetic Envy, Astra Peptides and Lone Star Peptide.
Lilly said retatrutide is in Phase 3 trials, lacks FDA approval and cannot be compounded or sold.
Customs intercepted over 690 shipments (31,000+ units) in FY 2025 and more than 1,400 shipments (?90,000 vials) in July.

1 of 1

Story summary

Eli Lilly filed six lawsuits in California and Texas against U.S. sellers of black-market retatrutide.
The suits target six entities, including Aesthetic Envy, Astra Peptides and Lone Star Peptide.
Lilly said retatrutide is in Phase 3 trials, lacks FDA approval and cannot be compounded or sold.
Customs intercepted over 690 shipments (31,000+ units) in FY 2025 and more than 1,400 shipments (?90,000 vials) in July.